Agoracom Blog Home

Posts Tagged ‘Proposition 207’

Hollister Biosciences $HOLL.ca $HSTRF 100% Owned Subsidiary Venom Extracts Achieves Final $40 Million Revenue Milestone $CRON $GTBIF $INDS $META.ca $FAF.ca $WEED.ca

Posted by AGORACOM-JC at 7:11 AM on Thursday, December 10th, 2020
https://prnewswire2-a.akamaihd.net/p/1893751/sp/189375100/thumbnail/entry_id/1_dd2snc3b/def_height/400/def_width/400/version/100011/type/1
  • Announced that further to the news release dated March 30th , 2020, its 100% owned subsidiary, Venom Extracts has achieved its second of two revenue milestones in accordance with the terms of the definitive agreement that was entered in connection with the acquisition of Venom by the Company
  • On December 9th , 2020, Venom achieved the second and final revenue milestone by generating in excess of CDN $40,000,000 of revenue calculated from January 1 st , 2020.

VANCOUVER, BC , Dec. 10, 2020 – Hollister Biosciences Inc. (CSE: HOLL) (OTCPK: HSTRF) (FRANKFURT: HOB) (the ” Company “, ” Hollister Cannabis Co .” or ” Hollister “) a diversified cannabis branding company with products in over 230 dispensaries throughout California , and over 80 dispensaries throughout Arizona , is pleased to announce that further to the news release dated March 30 th , 2020, its 100% owned subsidiary, Venom Extracts (” Venom “) has achieved its second of two revenue milestones in accordance with the terms of the definitive agreement that was entered in connection with the acquisition of Venom by the Company (the ” Transaction “).

On December 9 th , 2020, Venom achieved the second and final revenue milestone by generating in excess of CDN$40,000,000 of revenue calculated from January 1 st , 2020. Hollister also reports that Venom generated CDN$ 4.8 million in adjusted EBITDA over the same period.  As a result, the Company will issue 9,870,018 common shares (the ” Earn-Out Shares “) to certain former Venom shareholders at a deemed price of $0.20 per Earn-Out Share. The Earn-Out Shares will not be subject to any hold period under applicable securities laws.

On November 4 th the state of Arizona passed Prop 207 authorizing the Adult Use of Cannabis. Arizona is a mature, limited license medical market with 123 Operational Dispensaries as of 10/31/20, and 287,715 patients reported as of September 2020 . “The victory also puts Arizona on pace to create one of the biggest new marijuana markets in the country. The Arizona recreational market could generate as much as USD $375 million – $400 million in its first year and $700 million – $760 million by 2024, according to projections by Marijuana Business Daily.”

Venom Extracts is a leading concentrate brand in Arizona , accounting for between 25-30% of category sales. Venom has 8 sku’s with varying product forms including; Shatter, Crystals, Nectar Sauce, Sugar Wax, Live Resin, Diamond Sauce , THC-A, and Vape Cartridges.  Venom products can be found in over 80 retail locations including Arizona’s market leader; Harvest Health and Recreation (CSE:HARV, OTCMKTS: HRVSF), leading multi-state cannabis operator Curaleaf  (CSE:CURA, OTCMKTS: CURLF), MUV by Atlmed and other leading dispensaries.

“We are very proud of the Arizona team and their ability to achieve this final revenue milestone and market leadership position.  We look forward to continuing the growth of our Arizona platform as it transitions to an adult use market.” shared Carl Saling , CEO of Hollister .

None of the securities to be issued pursuant to the Transaction have been or will be registered under the U.S. Securities Act of 1933, as amended (the ” U.S. Securities Act “), or any state securities laws, and any securities issued pursuant to the Transaction are anticipated to be issued in reliance upon available exemptions from such registration requirements pursuant to Rule 506(b) of Regulation D and/or Section 4(a)(2) of the U.S. Securities Act and applicable exemptions under state securities laws. In addition, the securities issued under an exemption from the registration requirements of the U.S. Securities Act will be “restricted securities” as defined under Rule 144(a)(3) of the U.S. Securities Act and will contain the appropriate restrictive legend as required under the U.S. Securities Act.

About Hollister Biosciences Inc.

Hollister Biosciences Inc. is a multi-state cannabis company with a vision to be the sought-after premium brand portfolio of innovative, high-quality cannabis & hemp products. Hollister uses a high margin model, controlling the whole process from manufacture to sales to distribution or seed to shelf. Products from Hollister Biosciences Inc. include HashBone, the brand’s premier artisanal hash-infused pre-roll, along with concentrates (shatter, budder, crumble), distillates, solvent-free bubble hash, pre-packaged flower, pre-rolls, tinctures, vape products, and full-spectrum high CBD pet tinctures. Hollister Cannabis Co. additionally offers white-labeling manufacturing of cannabis products.  Our wholly-owned California subsidiary Hollister Cannabis Co is the 1st state and locally licensed cannabis company in the city of Hollister, CA birthplace of the “American Biker”.

Website: www.hollistercannabisco.com

The CSE, nor its regulation services provider, does not accept responsibility for the adequacy or accuracy of this release.

Non-IFRS Financial Measures: This news release makes reference to certain non IFRS financial measures. These measures are not recognized measures under IFRS, do not have a standardized meaning prescribed by IFRS and are therefore unlikely to be comparable to similar measures presented by other companies. These measures are provided as additional information to complement the IFRS financial measures by providing further metrics to understand the Company’s results of operations from management’s perspective. Accordingly, they should not be considered in isolation nor as a substitute for analysis of our financial information reported under IFRS. We use non IFRS financial measures, including segmented revenue and adjusted EBITDA, to provide investors with supplemental measures of our operating performance and thus highlight trends in our core business that may not otherwise be apparent when relying solely on IFRS financial measures.

Forward-Looking Information: This news release includes certain statements that may be deemed “forward-looking statements”. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com

Hollister Biosciences $HOLL.ca $HSTRF Launches Direct to Consumer Cannabis Delivery Platform, Dreamy Delivery $CRON $GTBIF $INDS $META.ca $FAF.ca $WEED.ca

Posted by AGORACOM-JC at 8:15 AM on Tuesday, November 10th, 2020
https://prnewswire2-a.akamaihd.net/p/1893751/sp/189375100/thumbnail/entry_id/1_dd2snc3b/def_height/400/def_width/400/version/100011/type/1
  • Announced the launch of its direct to consumer cannabis delivery platform, Dreamy Delivery
  • Company soft launched Dreamy Delivery to friends and family in the San Francisco Bay Area of Northern California, to ensure a seamless customer experience in early Q4 of 2020
  • Company hopes to launch Dreamy in Sacramento and the Central Coast of California by late Q4 of 2020 with the ultimate goal of delivering Cannabis statewide

VANCOUVER, BC , Nov. 10, 2020 – Hollister Biosciences Inc. (CSE: HOLL) (OTC: HSTRF) (FRANKFURT: HOB) (the ” Company “, ” Hollister Cannabis Co. ” or ” Hollister “) a diversified cannabis branding company with products in over 280 dispensaries throughout California , and over 80 dispensaries throughout Arizona , is pleased to announce the launch of its direct to consumer cannabis delivery platform, Dreamy Delivery (” Dreamy ” or the ” Platform “).

The company soft launched Dreamy Delivery to friends and family in the San Francisco Bay Area of Northern California ( “Bay Area “), to ensure a seamless customer experience in early Q4 of 2020. The Company has expanded the Platform, with Dreamy now successfully delivering to legal cannabis consumers in the Bay Area. The Company hopes to launch Dreamy in Sacramento and the Central Coast of California by late Q4 of 2020 with the ultimate goal of delivering Cannabis statewide.

Carl Saling , CEO of Hollister , shared: “This is a major first step in our quest to be the dominant direct to consumer platform delivering cannabis to the entire state of California .”

Website: www.dreamydelivery.com

About Hollister Biosciences Inc.

Hollister Biosciences Inc. is a multi-state cannabis company with a vision to be the sought-after premium brand portfolio of innovative, high-quality cannabis & hemp products. Hollister uses a high margin model, controlling the whole process from manufacture to sales to distribution or seed to shelf. Products from Hollister Biosciences Inc. include HashBone, the brand’s premier artisanal hash-infused pre-roll, along with concentrates (shatter, budder, crumble), distillates, solvent-free bubble hash, pre-packaged flower, pre-rolls, tinctures, vape products, and full-spectrum high CBD pet tinctures. Hollister Cannabis Co. additionally offers white-labeling manufacturing of cannabis products. Our wholly owned California subsidiary Hollister Cannabis Co is the 1st state and locally licensed cannabis company in the city of Hollister, CA birthplace of the “American Biker”.

Website: www.hollistercannabisco.com

The CSE, nor its regulation services provider, does not accept responsibility for the adequacy or accuracy of this release.

Forward-Looking Information: This news release includes certain statements that may be deemed “forward-looking statements”. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com .

VIDEO – Hollister $HOLL.ca $HSTRF Reports Record Q3 Revenues With $12.5M From 360+ Dispensaries In California and Arizona $CRON $GTBIF $INDS $META.ca $FAF.ca $WEED.ca

Posted by AGORACOM-JC at 4:23 PM on Monday, November 9th, 2020
https://prnewswire2-a.akamaihd.net/p/1893751/sp/189375100/thumbnail/entry_id/1_dd2snc3b/def_height/400/def_width/400/version/100011/type/1

Hollister Biosciences (HOLL:CSE) is a multi-state operator with multiple, high-quality products that are now carried in 280 of California’s 600 dispensaries, where it also claims California’s #1 hash infused pre-roll “HashBone” … and if that is all they had you would have the makings of a great small cap cannabis company. 

But there is more …. way more. 

Venom Extracts is their 100% owned subsidiary that is absolutely dominating the state of Arizona.  More than just lip service:

  • Venom just surpassed $30,000,000 (MILLION) in revenue YEAR TO DATE
  • Venom Extracts is one of Arizona’s premier extract brands 
  • One of the state’s largest producers of medical cannabis distillate and related products
  • The products are award winning
  • ….. And it is run by the absolute coolest guy in small cap Cannabis – Jake Cohen  

THE NUMBERS SAY IT ALL 

1.  RECORD Q3 REVENUE          $12.5M 

2.  CRAZY REVENUE GROWTH    5,200%

3.  RECORD EBITDA                 $1.265M (vs a loss of $362,000) In case you’re wondering if this was a fluke quarter, this is what Q2 looked like: 

  • RECORD REVENUE of $US 8.47M, compared to $200,000 last year and representing an increase of 4,170%
  • NET INCOME of $300,000, compared to a loss of $2.1M, representing a turnaround of $2.4M over last year 

HOLLISTER HEADED TOWARDS $50,000,000 REVENUE? 

If you’re paying attention, HOLL is achieving enormous growth both year over year and sequentially.  If we extrapolate the latest Q3 numbers, Hollister is on a $50,000,000 annualized revenue run rate assuming no further growth. 

But there is more. 

The State of Arizona just approved recreational cannabis in Arizona.  This is a potential windfall for Venom given the fact its brand, reputation and dispensary penetration from its award winning medical cannabis is about as good as it gets.  How good is Hollister now? 

How good does it get? 

Watch this incredible interview with Venom Extracts Founder Jake Cohen, the coolest exec in small cap cannabis because he delivers incredible results with sweat, swagger and great swag to boot.  

Watch this interview or listen by Podcast on AppleGoogleSpotify or your favourite podcaster.

Hollister $HOLL.ca $HSTRF Provides Comment on Approval of Recreational Cannabis in Arizona $CRON $GTBIF $INDS $META.ca $FAF.ca $WEED.ca

Posted by AGORACOM-JC at 10:58 PM on Wednesday, November 4th, 2020
https://prnewswire2-a.akamaihd.net/p/1893751/sp/189375100/thumbnail/entry_id/1_dd2snc3b/def_height/400/def_width/400/version/100011/type/1
  • Company comments on the successful passage of Proposition 207 – legalizing the cultivation, sale and consumption of recreational cannabis in the state of Arizona
  • “Seeing recreational Cannabis legalized in the state is an encouraging sign and is hopefully another step toward federal legalization. It should lead to increased tax revenue and job creation. The recreational cannabis market in Arizona could be valued at up to US $760 million by 2024…” Shared Jacob Cohen , Founder of Venom Extracts, Hollister’s 100% owned subsidiary based in Arizona .

VANCOUVER, BC , Nov. 4, 2020 – Hollister Biosciences Inc. (CSE: HOLL) (OTC: HSTRF) (FRANKFURT: HOB) (the ” Company “, ” Hollister Cannabis Co. ” or ” Hollister “) a diversified cannabis branding company with products in over 280 dispensaries throughout California , and over 80 dispensaries throughout Arizona provides comment on the successful passage of Proposition 207 – legalizing the cultivation, sale and consumption of recreational cannabis in the state of Arizona .

“Seeing recreational Cannabis legalized in the state is an encouraging sign and is hopefully another step toward federal legalization. It should lead to increased tax revenue and job creation. The recreational cannabis market in Arizona could be valued at up to US $760 million by 2024 1 , significantly expanding the total addressable market for Cannabis in the state. We look forward to making our product line available to both the medical and recreational end user.” Shared Jacob Cohen , Founder of Venom Extracts, Hollister’s 100% owned subsidiary based in Arizona .

Arizona Presence

Hollister , through its 100% owned subsidiary, Venom Extracts (” Venom “), is one of Arizona’spremier extract brands and one of the state’s largest producers of award-winning medical cannabis distillate and related products. With an experienced management team and unparalleled reputation for quality, Venom prides itself as a differentiated extraction company by producing legal cannabis products at a price point that allows retailers to generate higher profits. Focused on proprietary efficiencies, Venom is able to produce more product per square foot than its competition, maintaining lower costs and risks than a typical extraction company.

Website: www.venomextracts.com

About Hollister Biosciences Inc.

Hollister Biosciences Inc. is a multi-state cannabis company with a vision to be the sought-after premium brand portfolio of innovative, high-quality cannabis & hemp products. Hollister uses a high margin model, controlling the whole process from manufacture to sales to distribution or seed to shelf. Products from Hollister Biosciences Inc. include HashBone, the brand’s premier artisanal hash-infused pre-roll, along with concentrates (shatter, budder, crumble), distillates, solvent-free bubble hash, pre-packaged flower, pre-rolls, tinctures, vape products, and full-spectrum high CBD pet tinctures. Hollister Cannabis Co. additionally offers white-labeling manufacturing of cannabis products. Our wholly owned California subsidiary Hollister Cannabis Co is the 1st state and locally licensed cannabis company in the city of Hollister, CAbirthplace of the “American Biker”.

Website www.hollistercannabisco.com

The CSE, nor its regulation services provider, does not accept responsibility for the adequacy or accuracy of this release.

Forward-Looking Information: This news release includes certain statements that may be deemed “forward-looking statements”. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com

 
Source:  Marijuana Business Daily

 View original content to download multimedia: http://www.prnewswire.com/news-releases/hollister-provides-comment-on-approval-of-recreational-cannabis-in-arizona-301166780.html

SOURCE Hollister Biosciences Inc.